Induction of IDO1 and Kynurenine by Serine Proteases Subtilisin, Prostate Specific Antigen, CD26 and HtrA: A New Form of Immunosuppression?

• Published in: Frontiers in immunology Vol. 13; p. 832989
• Main Authors: Clanchy, Felix I L, Huang, Yi-Shu, Ogbechi, Joy, Darlington, L Gail, Williams, Richard O, Stone, Trevor W
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.03.2022
• Subjects: Animals; CD26; Cytokines; Dipeptidyl Peptidase 4 - genetics; Humans; IDO1; Immunology; Immunosuppression Therapy; Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism; kynurenine; Kynurenine - metabolism; Male; Mammals - metabolism; Neoplasms; Prostate Specific Antigen; PSA; Serine Proteases; Staphylococcal Protein A; Subtilisin; DPP4; Prostate Specific Antigen; HtrA; CD26; kynurenine; serine proteases; IDO1; PSA
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.832989

Several serine proteases have been linked to autoimmune disorders and tumour initiation although the mechanisms are not fully understood. Activation of the kynurenine pathway enzyme indoleamine-2,3-dioxygenase (IDO1) modulates cellular activity in the brain, tolerogenesis in the immune system and is a major checkpoint in cancer development. We now report that mRNA and IDO1 protein expression (generating kynurenine) are induced in human monocyte-derived macrophages by several chymotryptic serine proteases with direct links to tumorigenesis, including Prostate Specific Antigen (PSA), CD26 (Dipeptidyl-peptidase-4, CD26/DPP-4), High Temperature Requirement protein-A (HtrA), and the bacterial virulence factor subtilisin. These proteases also induce expression of the pro-inflammatory cytokine genes and . Other serine proteases tested: bacterial glu-C endopeptidase and mammalian Pro-protein Convertase Subtilase-Kexin-3 (PCSK3, furin), urokinase plasminogen activator (uPA), cathepsin G or neutrophil elastase, did not induce , indicating that the reported effects are not a general property of all serine proteases. The results represent a novel mechanism of activating immunosuppressive and inducing kynurenine generation which, together with the production of inflammatory cytokines, would contribute to tumour initiation and progression, providing a new target for drug development. In addition, the proteasomal S20 serine protease inhibitor carfilzomib, used in the treatment of myeloma, prevented the induction of and cytokine gene expression, potentially contributing to its clinical anti-cancer activity.